This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Stephen Spagnol, PhD
Director, Enabling Technologies at Merck


Stephen Spagnol is a Director of Business Development & Licensing, Enabling Technologies Search and Evaluation at Merck. His current work focuses on search and evaluation efforts related to mRNA/RNA, drug delivery, formulation, bioprocess and cell & gene therapy. Prior to returning to Merck, Stephen was an Associate Director at Johnson & Johnson where he led efforts spanning novel and new modality therapeutics. This included Phase III and late-stage development for AAV gene therapy programs as well as development efforts for oncolytic viruses and viral vaccines for oncology. He also led novel platform development for AAV gene therapy culminating in several patent applications. Stephen started his career at Merck, and most recently was an Associate Principal Scientist serving as a scientific supervisor and led formulation and process development efforts for RNA therapeutics and mRNA vaccines. He also led formulation efforts for design and optimization of novel drug delivery technologies for RNA therapeutics and mRNA vaccines.

Stephen received a Ph.D. in Chemical Engineering from Carnegie Mellon University. Stephen completed his B.S. degree in Chemical Engineering from the Pennsylvania State University.

Agenda Sessions

  • Chairman’s Remarks: Next-Generation Delivery Platforms